Budesonide - Sigma Pharmaceuticals Plc

SIGMA Pharmaceuticals

Description

Prophylaxis and treatment of allergic rhinitis and nasal polyps by intranasal administration
• Over 6 years: 256 mcg once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved. Alternatively, 128 mcg twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.

Prophylaxis of asthma by nebulised suspension
• Child 6 months–11 years: 125–500 mcg twice daily, dose to be adjusted as required. Maximum 2 mg per day.
• Over 12 years: initially 0.25–1 mg twice daily, dose to be adjusted as required. Maximum 2 mg per day.

Prophylaxis of mild to moderate asthma by inhalation of powder
• Child 6 months–11 years: 200–400 micrograms once daily, dose to be given in the evening.
• Over 12 years: 200–400 micrograms once daily (max. per dose 800 micrograms), dose to be given in the evening.

Prophylaxis of asthma by inhalation of powder
• Child 6 months–11 years: 100–400 micrograms twice daily, dose to be adjusted as necessary.
• Over 12 years: 100–800 micrograms twice daily, dose to be adjusted as necessary.

Prophylaxis as treatment of allergic and vasomotor rhinitis by intranasal administration
• Child 6-17 years: 256 micrograms once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved, alternatively 128 micrograms twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.
• Adult: 256 micrograms once daily, to be administered as 2 sprays into each nostril in the morning, reduce dose when control achieved, alternatively 128 micrograms twice daily, to be administered as 1 spray into each nostril in the morning and in the evening, reduce dose when control achieved.